| Year - Ending | Revenue | Operating Income | Net Income |
| Dec-2022 | 751 | 20 | -175 (Loss) |
| Dec-2021 | 618 | 41 | 215 |
| Dec-2020 | 500 | 51 | 6 |
| Dec-2019 | 446 | 74 | 38 |
| Dec-2018 | 375 | 62 | 84 |
Evotec SE
EVT.DEEvotec SE in brief
Evotec SE is a listed company in the Pharmaceutical industry, based in Germany. It was founded in 1993. Its market value was $720 M on 1 August 2026, which makes it the 10,960th largest listed company in the world and the 173rd largest in Germany on this site. In the year to December 2024 it had sales of $862 M and a net loss of $212 M. It employs about 4,952 people. Its largest product and service lines by sales in 2025 were Fee for service and FTE-based research services (78%), Licences (16%) and Material re-charges to customers (4%). By market, the largest shares of its 2025 sales came from USA (55%), Switzerland (20%) and UK (8%). Its shares trade under the symbol EVT.DE (Deutsche Borse).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Evotec SE
Evotec is a drug discovery alliance and development partnership company focused on innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups. Headquarters is in Germany.
As on 2020, Evotec has 3,030 employees across 14 countries.
Evotec has long-term discovery alliances with partners including Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB.
Evotec SE timeline
- 1993
- 🏁
- 2014
- •Legal Entity Identifier issuedLEI 529900F9KI6OYITO9B12 registered.
Events of Evotec SE from Wikidata and the GLEIF LEI register. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in Germany: #93 (Jan 2020) · #83 (Jan 2021) · #72 (Jan 2022) · #93 (Dec 2022) · #74 (Jul 2023) · #85 (Jan 2024) · #175 (Aug 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 0.8×
- Price / book
- 0.7×
- Free cash flow yield
- -14.9%
- Net margin (TTM)
- -24.6%
- Operating margin
- -17.9%
- Return on equity
- -21.4%
- Liabilities / assets
- 50.2%
- Net debt
- $-93M
- Revenue growth
- +2.1%
- R&D / revenue
- 6.4%
- Revenue per employee
- $174 K
- Profit per employee
- $-43 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2024 | $862M | +2.1% | $-154M | $-212M | -24.6% |
| Dec 2023 | $845M | +7.0% | $-51M | $-91M | -10.7% |
| Dec 2022 | $790M | +8.1% | $22M | $-185M | -23.4% |
| Dec 2021 | $731M | +27.9% | $48M | $255M | 34.9% |
| Dec 2020 | $571M | +14.3% | $55M | $7M | 1.3% |
| Dec 2019 | $500M | — | $70M | $43M | 8.5% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2024 | $20M | $127M | $-107M | $-1.20 | — |
| Dec 2023 | $39M | $231M | $-191M | $-0.51 | — |
| Dec 2022 | $216M | $191M | $26M | $-1.04 | — |
| Dec 2021 | $150M | $141M | $9M | $1.54 | — |
| Dec 2020 | $51M | $113M | $-62M | $0.05 | — |
| Dec 2019 | $47M | $35M | $12M | $0.28 | — |
SEC filings
- Nov 5, 20266-KReport of foreign issuer
- Oct 15, 20266-KReport of foreign issuer
- Oct 14, 20266-KReport of foreign issuer
- Sep 29, 20266-KReport of foreign issuer
- Sep 9, 20266-KReport of foreign issuer
- Aug 13, 20266-KReport of foreign issuer
- Jul 14, 20266-KReport of foreign issuer
- Jun 30, 20266-KReport of foreign issuer
- Jun 17, 20266-KReport of foreign issuer
- May 6, 20266-KReport of foreign issuer
- Apr 30, 20266-KReport of foreign issuer
- Apr 24, 20266-KReport of foreign issuer
Official filings of Evotec SE with the US Securities and Exchange Commission.
Annual results
- Revenue
- $862 M
- Operating income
- $-154 M
- Net income
- $-212 M
For year ending December-2024 · source: SEC filing
Balance sheet
- Total assets
- $2.0 B
- Total liabilities
- $997 M
- Total equity
- $990 M
As of December-2024
EVOTEC SE - Yearly Revenue and Net Income - in Million EUR
Balance sheet
Total Assets as on Dec-2022 was 2,257 Million EUR.
Total Liabilities as on Dec-2022 was 1,070 Million EUR.
Total Equity as on Dec-2022 was 1,187 Million EUR.
Top 25 institutional investors in Evotec SE#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | DCF Advisers, LLC | 1,048,362 | -30,662 (-2.84%) | 0.29% | $2 M | Nov 4, 2026 |
| 2 | Abc Arbitrage SA | 541,106 | +169,170 (+45.48%) | 0.15% | $1 M | Oct 23, 2026 |
| 3 | Optiver Holding B.V. | 62,562 | -259,591 (-80.58%) | 0.02% | $0 M | Nov 16, 2026 |
| 4 | Fore Capital, LLC | 51,355 | +20,000 (+63.79%) | 0.01% | $0 M | Nov 13, 2026 |
| 5 | Morgan Stanley | 32,545 | -173,218 (-84.18%) | 0.01% | $0 M | Nov 13, 2026 |
| 6 | Millennium Management LLC | 26,517 | +3,684 (+16.13%) | 0.01% | $0 M | Nov 16, 2026 |
| 7 | SmartHarvest Portfolios, LLC | 25,173 | New | 0.01% | $0 M | Oct 26, 2026 |
| 8 | Old Mission Capital LLC | 22,948 | -15,084 (-39.66%) | 0.01% | $0 M | Nov 16, 2026 |
| 9 | XTX Topco Ltd | 21,688 | +3,797 (+21.22%) | 0.01% | $0 M | Nov 16, 2026 |
| 10 | Squarepoint Ops LLC | 20,480 | New | 0.01% | $0 M | Nov 9, 2026 |
| 11 | HRT Financial LP | 18,763 | New | 0.01% | $0 M | Nov 13, 2026 |
| 12 | BNP Paribas Financial Markets | 15,900 | +2,623 (+19.76%) | 0.00% | $0 M | Nov 12, 2026 |
| 13 | Virtu Financial LLC | 12,944 | New | 0.00% | $0 M | Nov 17, 2026 |
| 14 | CSS Llc/il | 12,100 | 0 (0.00%) | 0.00% | $0 M | Nov 16, 2026 |
| 15 | Geode Capital Management, LLC | 11,272 | 0 (0.00%) | 0.00% | $0 M | Nov 6, 2026 |
| 16 | Vanguard Personalized Indexing Management, LLC | 10,370 | -3,226 (-23.73%) | 0.00% | $0 M | Nov 16, 2026 |
| 17 | UBS Group AG | 1,815 | New | 0.00% | $0 M | Nov 10, 2026 |
| 18 | Rockefeller Capital Management L.P. | 704 | -9,515 (-93.11%) | 0.00% | $0 M | Nov 13, 2026 |
| 19 | Osaic Holdings, Inc. | 310 | -30 (-8.82%) | 0.00% | $0 M | Nov 12, 2026 |
| 20 | Jpmorgan Chase & Co | 100 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 21 | SBI Securities Co., Ltd. | 97 | +2 (+2.11%) | 0.00% | $0 M | Oct 22, 2026 |
| 22 | Farther Finance Advisors, LLC | 97 | +80 (+470.59%) | 0.00% | $0 M | Oct 8, 2026 |
| 23 | Strive Financial Group ,LLC | 41 | 0 (0.00%) | 0.00% | $0 M | Nov 9, 2026 |
| 24 | Silver Grove Financial Group, Inc. | 25 | 0 (0.00%) | 0.00% | $0 M | Nov 5, 2026 |
| 25 | Caitong International Asset Management Co., Ltd | 19 | +16 (+533.33%) | 0.00% | $0 M | Oct 29, 2026 |
Mutual funds holding Evotec SE#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 First Trust WCM International Equity ETFFirst Trust Advisors L.P. | 2.60 M | $15 M | 1.4% | 0.90% | +33% | Jun 30, 2026 |
| 🇺🇸 Brown Capital Management International Small Company FundBrown Capital Management, LLC | 2.00 M | $11 M | 1.1% | 1.7% | −48% | Jun 30, 2026 |
| 🇺🇸 Vanguard Total International Stock Index FundThe Vanguard Group, Inc. | 2.32 M | $9 M | 1.3% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Vanguard Developed Markets Index FundThe Vanguard Group, Inc. | 1.55 M | $9 M | 0.85% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 iShares Core MSCI EAFE ETFBlackRock Fund Advisors | 1.09 M | $4 M | 0.60% | <0.01% | +1.2% | Jul 31, 2026 |
| 🇺🇸 JNL Multi-Manager International Equity FundJackson National Asset Management, LLC | 530,535 | $3 M | 0.29% | 0.21% | new | Jun 30, 2026 |
| 🇺🇸 Vanguard Ftse All-World Ex-Us Small-Cap Index FundThe Vanguard Group, Inc. | 660,978 | $3 M | 0.36% | 0.02% | +7.9% | Jul 31, 2026 |
| 🇺🇸 Schwab International Small-Cap Equity ETFCharles Schwab Investment Management, Inc. | 339,204 | $2 M | 0.19% | 0.04% | +11% | May 31, 2026 |
| 🇺🇸 iShares MSCI EAFE Small-Cap ETFBlackRock Fund Advisors | 486,587 | $2 M | 0.27% | 0.01% | −13% | Jul 31, 2026 |
| 🇺🇸 Dfa International Small Cap Value PortfolioDimensional Fund Advisors LP | 477,830 | $2 M | 0.26% | 0.01% | no change | Jul 31, 2026 |
| 🇺🇸 WCM Focused International Equity FundWCM Investment Management, LLC | 320,000 | $2 M | 0.17% | 0.73% | — | Jun 30, 2026 |
| 🇺🇸 International Core Equity 2 PortfolioDimensional Fund Advisors LP | 414,281 | $2 M | 0.23% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Vanguard European Stock Index FundThe Vanguard Group, Inc. | 374,933 | $1 M | 0.20% | <0.01% | −2.9% | Jul 31, 2026 |
| 🇺🇸 First American Multi-Manager International Equity FundU.S. Bancorp Asset Management, Inc. | 234,816 | $1 M | 0.13% | 0.14% | −7.4% | Jun 30, 2026 |
| 🇺🇸 Dimensional International Small Cap Value ETFDimensional Fund Advisors LP | 340,378 | $1 M | 0.19% | 0.03% | no change | Jul 31, 2026 |
| 🇺🇸 Diamond Hill International FundDiamond Hill Capital Management, Inc. | 215,817 | $1 M | 0.12% | 0.72% | no change | Jun 30, 2026 |
| 🇺🇸 iShares Core MSCI Total International Stock ETFBlackRock Fund Advisors | 250,538 | $1 M | 0.14% | <0.01% | +1.4% | Jul 31, 2026 |
| 🇺🇸 Dimensional International Small Cap ETFDimensional Fund Advisors LP | 247,236 | $1 M | 0.14% | 0.02% | +6.5% | Jul 31, 2026 |
| 🇺🇸 iShares Core MSCI International Developed Markets ETFBlackRock Fund Advisors | 236,942 | $1 M | 0.13% | <0.01% | +4.7% | Jul 31, 2026 |
| 🇺🇸 State Street SPDR Portfolio Developed World ex-US ETFSSGA Funds Management, Inc. | 139,716 | $1 M | 0.08% | <0.01% | −0.1% | Jun 30, 2026 |
| 🇺🇸 College Retirement Equities Fund - Total Global Stock AccountTIAA-CREF Investment Management, LLC | 99,443 | $1 M | 0.05% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Dimensional International Core Equity 2 ETFDimensional Fund Advisors LP | 140,274 | $1 M | 0.08% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Vanguard Total World Stock Index FundThe Vanguard Group, Inc. | 139,635 | $1 M | 0.08% | <0.01% | +37% | Jul 31, 2026 |
| 🇺🇸 State Street SPDR S&P International Small Cap ETFSSGA Funds Management, Inc. | 86,839 | $0 M | 0.05% | 0.06% | +1.0% | Jun 30, 2026 |
| 🇸🇪 Handelsbanken Global Småbolag Index CriteriaHandelsbanken Fonder AB | 78,600 | $0 M | 0.04% | 0.01% | +23% | Jun 30, 2026 |
| 🇺🇸 iShares Core MSCI Europe ETFBlackRock Fund Advisors | 109,529 | $0 M | 0.06% | <0.01% | −2.1% | Jul 31, 2026 |
| 🇺🇸 Dimensional World ex. U.S. Core Equity 2 ETFDimensional Fund Advisors LP | 100,763 | $0 M | 0.06% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Fidelity Total International Index FundFidelity Management & Research Company LLC | 80,033 | $0 M | 0.04% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Dimensional International Core Equity Market ETFDimensional Fund Advisors LP | 70,485 | $0 M | 0.04% | <0.01% | −11% | Jul 31, 2026 |
| 🇺🇸 Vanguard Esg International Stock ETFThe Vanguard Group, Inc. | 37,348 | $0 M | 0.02% | <0.01% | +44% | May 31, 2026 |
| 🇺🇸 State Street Global All Cap Equity ex-U.S. Index PortfolioSSGA Funds Management, Inc. | 36,261 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 World ex U.S. Core Equity PortfolioDimensional Fund Advisors LP | 45,380 | $0 M | 0.02% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Fidelity SAI International Small Cap Index FundFidelity Management & Research Company LLC | 39,176 | $0 M | 0.02% | 0.01% | −2.7% | Jul 31, 2026 |
| 🇺🇸 Invesco RAFI Developed Markets ex-U.S. Small-Mid ETFInvesco Capital Management LLC | 20,572 | $0 M | 0.01% | 0.02% | +3.5% | Jul 31, 2026 |
| 🇺🇸 International Vector Equity PortfolioDimensional Fund Advisors LP | 16,930 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 State Street SPDR Portfolio MSCI Global Stock Market ETFSSGA Funds Management, Inc. | 11,018 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 iShares MSCI Europe Small-Cap ETFBlackRock Fund Advisors | 15,279 | $0 M | <0.01% | 0.03% | −11% | Jul 31, 2026 |
| 🇺🇸 Dimensional VA International Small PortfolioDimensional Fund Advisors LP | 15,101 | $0 M | <0.01% | 0.01% | no change | Jul 31, 2026 |
| 🇺🇸 iShares MSCI World Small-Cap ETFBlackRock Fund Advisors | 8,434 | $0 M | <0.01% | <0.01% | −25% | May 31, 2026 |
| 🇺🇸 International Sustainability Core 1 PortfolioDimensional Fund Advisors LP | 10,829 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Brighthouse/Dimensional International Small Company PortfolioBrighthouse Investment Advisers, LLC | 7,183 | $0 M | <0.01% | <0.01% | +98% | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 12,780 | $0 M | — | <0.01% | +84% | May 31, 2026 |
| 🇺🇸 State Street SPDR Portfolio Europe ETFSSGA Funds Management, Inc. | 6,491 | $0 M | <0.01% | <0.01% | −2.3% | Jun 30, 2026 |
| 🇺🇸 Dimensional International Sustainability Core 1 ETFDimensional Fund Advisors LP | 9,212 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 International Small Company TrustJohn Hancock Variable Trust Advisers LLC | 5,066 | $0 M | <0.01% | 0.02% | +236% | Jun 30, 2026 |
| 🇺🇸 The Continental Small Company SeriesDimensional Fund Advisors LP | 6,914 | $0 M | <0.01% | <0.01% | −97% | Jul 31, 2026 |
| 🇺🇸 LVIP Dimensional International Core Equity FundLincoln Financial Investments Corporation | 3,436 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 AZL DFA International Core Equity FundAllianz Investment Management LLC | 2,062 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Dimensional International Vector Equity ETFDimensional Fund Advisors LP | 2,768 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 49 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Ownership and subsidiaries
- EVOTEC (UK) LIMITED🇬🇧 Abingdon
- Evotec (France) SAS🇫🇷 Toulouse
- Evotec International GmbH🇩🇪 Hamburg
Markets and events: Evotec SE#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Fails to deliver
- : 2,960 shares at $1.37
- : 700 shares at $1.63
- : 671 shares at $1.66
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Evotec SE scorecard#
Passes 5 of the 12 checks that could be worked out: strongest in growth (4 of 6), weakest in profitability (0 of 5). Fiscal year 2024; market cap of Aug 1, 2026.
Valuationnot known
- –P/E below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Price to book below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Price to sales below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Free cash flow yield above 5%The market cap dates from 2026-08-01, more than 60 days ago.
- –Earnings yield above the 10-year Treasury yieldThe market cap dates from 2026-08-01, more than 60 days ago.
- –The price assumes slower growth than the last three years'The market cap dates from 2026-08-01, more than 60 days ago.
Growth4 of 6
- ✓Revenue grew in the newest year2.1%Revenue up 2.1% in fiscal 2024.
- ✓Revenue up more than 5% a year over three years5.7%5.7% a year over the three years to fiscal 2024.
- ✓Faster growth over three years than its peers' median5.7%5.7% a year against Pharmaceutical's median of 2.5% (65 companies).
- ✗Earnings per share grew in the newest year-1.20 vs -0.51Diluted EPS -1.20 in fiscal 2024 against -0.51 the year before (report's currency).
- ✗Net income higher than five years earlier-$212 M-$212 M in fiscal 2024 against $43 M in 2019.
- ✓Revenue rose in at least four of the last five years5 of 5Revenue rose in 5 of the five years to fiscal 2024.
Profitability0 of 5
- ✗Profitable in the newest year-$212 MNet income -$212 M in fiscal 2024.
- ✗Profitable in each of the last five years2 of 5Profitable in 2 of the five years to fiscal 2024.
- ✗Operating margin above its peers' median-17.9%-17.9% against Pharmaceutical's median of 1.8% (74 companies).
- ✗Return on equity above 15%-19.1%-19.1% in fiscal 2024.
- –Return on invested capital above 10%No return on invested capital on file.
- ✗Operating margin wider than three years earlier-17.9%-17.9% in fiscal 2024 against 6.6% in 2021.
Financial health1 of 1
- –Short-term assets cover short-term liabilitiesCurrent assets and liabilities are not on file.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✓Cash from operations positive in each of the last three years3 of 3Positive in 3 of the three years to fiscal 2024.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returnsnot known
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- –Dividends and buybacks above 3% of the market valueThe market cap dates from 2026-08-01, more than 60 days ago.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Pharmaceutical, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2024#
Worked out from Evotec SE's statements, beside the median of Pharmaceutical.
| Ratio | Trend | 2024 | Median of peers |
|---|---|---|---|
| Operating margin | -17.9% | 1.8% | |
| Net margin | -24.6% | -1.5% | |
| Return on equity | -19.1% | -0.9% | |
| Revenue growth, 3 years a year | 5.7% | 2.5% | |
| Revenue growth | 2.1% | 7.3% | |
| Free cash flow margin | -12.5% | 6.0% |
3of 7on the Piotroski tests of financial strength
- Net loss of $212 million, the 3th loss-making year in a row.
- Free cash flow was negative: -$107 million.
- Revenue has grown 5 years in a row.
Evotec SE: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in EUR millions; per-share figures in EUR; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 797+2.0%100% | 781+4.0%100% | 751+21.6%100% | 618+23.4%100% | 501+12.2%100% | 446—100% | |
| Cost of revenue | 682+12.5%85.6% | 606+5.0%77.6% | 577+23.8%76.8% | 466+24.3%75.5% | 375+19.7%74.9% | 314—70.2% | |
| Gross profit | 115−34.4%14.4% | 175+0.6%22.4% | 174+14.9%23.2% | 152+20.5%24.5% | 126−5.4%25.1% | 133—29.8% | |
| Research and development | 51−25.8%6.4% | 69−10.6%8.8% | 77+6.2%10.2% | 72+12.9%11.7% | 64+9.4%12.8% | 58—13.1% | |
| Selling, general and administrative | 188+11.0%23.6% | 170+8.6%21.7% | 156+48.1%20.8% | 105+36.6%17.1% | 77+16.2%15.4% | 66—14.9% | |
| Selling and marketing | 17+3.6%2.2% | 17+25.0%2.2% | 13+43.2%1.8% | 9.4−0.9%1.5% | 9.5+4.5%1.9% | 9.1—2.0% | |
| Operating income | −143—−17.9% | −48−328%−6.1% | 21−49.1%2.8% | 41−15.6%6.6% | 49−22.6%9.7% | 63—14.0% | |
| Interest and finance income | — | — | 8.3+267%1.1% | 2.3+69.7%0.4% | 1.3−40.0%0.3% | 2.2—0.5% | |
| Interest expense and finance costs | — | — | 13+42.1%1.7% | 9.3+9.3%1.5% | 8.5+13.5%1.7% | 7.5—1.7% | |
| Income before tax | −194—−24.3% | −81—−10.3% | −154−165%−20.5% | 237+817%38.3% | 26−54.4%5.2% | 57—12.7% | |
| Income tax | 2.1−36.7%0.3% | 3.3−84.7%0.4% | 22+1.1%2.9% | 21+9.8%3.5% | 20+1.0%3.9% | 19—4.3% | |
| Net income including minority interests | −196—−24.6% | −84—−10.7% | −176−182%−23.4% | 216+3333%34.9% | 6.3−83.2%1.3% | 37—8.4% | |
| Minority interests' share of net income | — | — | — | — | — | −0.8—−0.2% | |
| Net income attributable to shareholders | — | — | −176−182%−23.4% | 216+3333%34.9% | 6.3−83.5%1.3% | 38—8.5% | |
| Earnings per share, basic | -1.11—— | -0.47—— | -0.99−176%— | 1.30+3150%— | 0.04−84.0%— | 0.25—— | |
| Earnings per share, diluted | -1.11—— | -0.47—— | -0.99−176%— | 1.30+3150%— | 0.04−84.0%— | 0.25—— | |
| Shares, weighted average (basic) | 177+0.2%— | 177+0.1%— | 177+6.2%— | 166+8.2%— | 154+2.7%— | 150—— | |
| Balance sheet | |||||||
| Cash and cash equivalents | 306−40.0%16.0% | 511+23.1%22.7% | 415−40.6%18.4% | 699+65.5%31.3% | 423+52.5%28.9% | 277—— | |
| Short-term investments | 90−3.0%4.7% | 93−69.3%4.1% | 303+90.9%13.4% | 159+168%7.1% | 59—4.1% | — | |
| Receivables | 116+18.2%6.1% | 98−42.7%4.4% | 172r169+30.1%7.6% | 132+67.2%5.9% | 79—5.4% | — | |
| Inventory | 31+0.8%1.6% | 31+3.6%1.4% | 30+15.6%1.3% | 26+89.9%1.2% | 14—0.9% | — | |
| Other current assets | 23−29.4%1.2% | 33−18.0%1.5% | 40+94.2%1.8% | 21−2.2%0.9% | 21—1.4% | — | |
| Current assets | 682−24.5%35.7% | 903−15.9%40.1% | 1,074−2.5%47.6% | 1,101+67.1%49.3% | 659—45.1% | — | |
| Property, plant and equipment | — | — | 650+34.2%28.8% | 485+43.7%21.7% | 337+41.0%23.1% | 239—— | |
| Right-of-use (leased) assets | — | — | 168+16.1%7.5% | 145+2.1%6.5% | 142—9.7% | — | |
| Goodwill | 283+2.6%14.8% | 276+0.3%12.2% | 275+6.7%12.2% | 258+4.1%11.5% | 247−3.3%16.9% | 256—— | |
| Other intangible assets | 26+71.1%1.4% | 15−35.1%0.7% | 24−22.8%1.1% | 31−68.5%1.4% | 98−16.2%6.7% | 117—— | |
| Investments in associates | 2.1−30.4%0.1% | 3.1−80.9%0.1% | 16+22.8%0.7% | 13−67.1%0.6% | 40+33.4%2.7% | 30—— | |
| Non-current assets | 1,231−8.8%64.3% | 1,349+14.0%59.9% | 1,184+4.4%52.4% | 1,134+41.2%50.7% | 803—54.9% | — | |
| Total assets | 1,913−15.1%100% | 2,252−0.2%100% | 2,257+1.0%100% | 2,235+52.8%100% | 1,462—100% | — | |
| Accounts payable | 86−36.1%4.5% | 134+38.1%6.0% | 97—4.3% | — | — | — | |
| Debt due within a year | — | — | 1.6−95.7%0.1% | 36+135%1.6% | 15—1.1% | — | |
| Current liabilities | 345−25.8%18.0% | 465+37.6%20.6% | 338+4.1%15.0% | 325+55.7%14.5% | 208—14.3% | — | |
| Long-term debt | — | — | 328+0.6%14.5% | 326−1.4%14.6% | 331—22.6% | — | |
| Lease liabilities (non-current) | 132−22.2%6.9% | 170+5.0%7.5% | 162+19.1%7.2% | 136+3.8%6.1% | 131—9.0% | — | |
| Non-current liabilities | 615−7.9%32.2% | 668−8.8%29.7% | 732+37.4%32.4% | 533+0.7%23.8% | 529—36.2% | — | |
| Retained earnings | −672—−35.2% | −476—−21.1% | −392—−17.4% | −216—−9.7% | −433—−29.6% | — | |
| Shareholders' equity | 953−14.9%49.8% | 1,120−5.7%49.7% | 1,187−13.8%52.6% | 1,378+90.2%61.6% | 724—49.5% | — | |
| Total equity | 953−14.9%49.8% | 1,120−5.7%49.7% | 1,187−13.8%52.6% | 1,378+90.2%61.6% | 724+51.4%49.5% | 479—— | |
| Total liabilities and equity | 1,913−15.1%100% | 2,252−0.2%100% | 2,257+1.0%100% | 2,235+52.8%100% | 1,462—100% | — | |
| Shares outstanding | 178+0.2%— | 177+0.1%— | 177+0.2%— | 177+7.7%— | 164—— | — | |
| Cash-flow statement | |||||||
| Depreciation and amortization | 102+9.3%12.8% | 93+11.8%11.9% | 83+18.2%11.1% | 70—11.4% | — | — | |
| Share-based compensation | 5.0−47.7%0.6% | 9.6−2.9%1.2% | 9.9+27.1%1.3% | 7.8+47.7%1.3% | 5.3+44.8%1.1% | 3.6—0.8% | |
| Cash from operating activities | 18−50.0%2.3% | 36−82.3%4.7% | 206r203+62.6%27.4% | 127r122+183%20.5% | 45+5.9%8.9% | 42—9.5% | |
| Capital expenditure | −117—−14.7% | −213—−27.3% | −181—−24.1% | −119—−19.2% | −99—−19.8% | −31—−7.0% | |
| Intangible assets bought | −15—−1.9% | −2.7—−0.3% | — | — | — | −0.6—−0.1% | |
| Acquisitions, net of cash acquired | — | −2.1—−0.3% | −21—−2.8% | −0.4—−0.1% | −11—−2.2% | −40—−9.0% | |
| Cash from investing activities | −71—−8.9% | −13—−1.7% | −413r−416—−54.9% | −243r−244—−39.3% | −155—−31.0% | −87—−19.4% | |
| Debt issued | 0.9−99.6%0.1% | 220—28.1% | — | 31+43.0%5.0% | 22−92.6%4.3% | 292—65.5% | |
| Debt repaid | −129—−16.2% | −113—−14.4% | −34—−4.5% | −16—−2.6% | −6.5—−1.3% | −70—−15.7% | |
| Shares issued | — | — | 0.4−99.9%0.0% | 403+61.3%65.2% | 250—49.9% | — | |
| Cash from financing activities | −161−324%−20.3% | 72—9.2% | −58r−52−115%−7.7% | 393r398+59.5%63.6% | 246+16.6%49.2% | 211—47.3% | |
| Exchange-rate effect on cash | 9.9+1432%1.2% | 0.6—0.1% | −19—−2.5% | −0.1−101%−0.0% | 9.5+738%1.9% | 1.1—0.3% | |
| Report | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Dec 31, 2024. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Evotec SE sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- Fee for service and FTE-based research services$691 M78%-13%
- Licences$138 M16%+3970%
- Material re-charges to customers$36 M4.0%-14%
- Milestone fees$11 M1.2%+249%
- Other fees$0 M0.0%-42%
Business segments
- Discovery & Preclinical Development$597 M67%-9.8%
- Just - Evotec Biologics$293 M33%+46%
Countries and regions
- 🇺🇸 USA$487 M55%+0.9%
- 🇨🇭 Switzerland$182 M21%+54%
- Rest of the world$87 M9.8%-2.4%
- 🇬🇧 UK$70 M7.8%-30%
- 🇩🇪 Germany$29 M3.2%-20%
- 🇫🇷 France$22 M2.5%+3.9%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Where Evotec SE operates: 6 countries#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 4 subsidiaries on file.
| Country | Presence | Revenue there |
|---|---|---|
| 🇩🇪 Germany | Headquarters2 offices1 subsidiary | $29 M3.2% |
| 🇮🇹 Italy | 1 subsidiary | — |
| 🇺🇸 USA | $487 M55% | |
| 🇨🇭 Switzerland | $182 M21% | |
| 🇬🇧 UK | 1 subsidiary | $70 M7.8% |
| 🇫🇷 France | 1 subsidiary | $22 M2.5% |
Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided
Discuss Evotec SE#
1 automatic updates and 0 member comments. Sign in to comment and react.
- Mutual funds: 49 funds hold $78 millionautomatic update · Jul 31, 2026
49 mutual funds in 2 countries hold shares of Evotec SE worth $78 million, about 8.8% of the company (funds' newest reports, up to 31 July 2026). Since their previous reports 17 funds added shares and 12 sold; on balance they sold $4 million. Share splits are not counted as trading.
How Evotec SE compares in Pharmaceutical
- Market cap$720 M · higher than 43% of 393
- Revenue$862 M · higher than 61% of 324
- Net margin-24.6% · higher than 13% of 313
- Revenue growth2.1% · higher than 36% of 107
- Price / sales0.8× · lower than 89% of 219
- Price / book0.7× · lower than 91% of 207
- FCF yield-14.9% · higher than 21% of 69
Peer comparison · Pharmaceutical
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Evotec SE🇩🇪 | $720 M | — | -24.6% | +2.1% |
| Eli Lilly and Company🇺🇸 | $1.20 T | 43.4× | 31.9% | +44.7% |
| Johnson & Johnson🇺🇸 | $652.5 B | 40.5× | 16.2% | +6.0% |
| AbbVie Inc.🇺🇸 | $514.0 B | 49.7× | 15.7% | +8.6% |
| Roche Holding AG🇨🇭 | $370.3 B | 29.1× | 19.0% | — |
| Merck & Co., Inc.🇺🇸 | $359.8 B | 146.7× | 3.6% | +1.3% |
| Novartis AG🇨🇭 | $286.8 B | 20.5× | 24.7% | — |
| Amgen Inc.🇺🇸 | $249.2 B | 26.5× | 24.1% | +9.9% |
| AstraZeneca PLC🇬🇧 | $242.6 B | 23.7× | 17.4% | +8.6% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
Sources and freshness
- Market cap:
- Aug 1, 2026
- Annual results:
- For year ending December-2024
- Balance sheet:
- As of December-2024
- Employees:
- As on 2022
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, Wikimedia Commons, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Evotec SE? Verify and update this profile — free
Show Evotec SE's ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.